Aug. 2, 2022 Price forecast | 2 weeks: -0.25% | 1 month: -0.20% | 3 months: -1.02%


PSNL stock forecast

Our latest prediction for Personalis Inc's stock price was made on the Aug. 2, 2022 when the stock price was at 4.07$.

In the short term (2weeks), PSNL's stock price should underperform the market by -0.25%. During that period the price should oscillate between -8.92% and +12.32%.

In the medium term (3months), PSNL's stock price should underperform the market by -1.02%. During that period the price should oscillate between -19.92% and +20.23%.

Create a solid portfolio with PSNL

Add PSNL to your portfolio and optimize it!


About Personalis Inc

Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the VA MVP. In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient's cancer and immune response. The Personalis® ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The PersonalisClinical Laboratory is GxP-aligned as well as CLIA'88-certified and CAP-accredited.

At the moment the company doesn't generate any revenue.

On its last earning announcement, the company reported a loss of -0.82$ per share.

The book value per share is 3.13$

Personalis Inc website


Three months stock forecastAug. 2, 2022


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
- - -94M - -93M -0.82 - - 45M 3.13 - - -